Paragon 28, Inc. (FNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paragon 28, Inc. (FNA) with AI Score 51/100 (Hold). Paragon 28, Inc. specializes in designing, developing, and distributing surgical solutions for the foot and ankle market. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Paragon 28, Inc. (FNA) Healthcare & Pipeline Overview
Paragon 28, Inc. focuses on the foot and ankle surgical systems market, offering plating systems, precision guide technology, and orthobiologics. With a gross margin of 73.5%, the company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors in the United States and internationally.
Investment Thesis
Paragon 28, Inc. presents a focused investment opportunity within the foot and ankle surgical market. The company's high gross margin of 73.5% indicates strong pricing power and efficient operations. Growth will be driven by the increasing prevalence of foot and ankle disorders, an aging population, and the demand for minimally invasive surgical techniques. Key value drivers include continued product innovation, expansion of the sales network, and strategic acquisitions to broaden the product portfolio. However, the company's negative profit margin of -17.5% and high beta of 1.47 suggest potential risks associated with profitability and market volatility. Investors should monitor the company's ability to achieve profitability and manage its operating expenses effectively.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $1.10B reflects investor valuation of Paragon 28's growth potential in the foot and ankle surgical market.
- Gross Margin of 73.5% indicates strong pricing power and efficient cost management in its product offerings.
- P/E Ratio of -46.49 indicates that the company is currently not profitable, requiring further analysis of its path to profitability.
- Beta of 1.47 suggests higher volatility compared to the market, potentially due to its growth stage and market sensitivity.
- Operates in the growing medical devices industry, specifically focusing on foot and ankle surgical solutions, positioning it within a specialized market segment.
Competitors & Peers
Strengths
- Specialized focus on the foot and ankle market.
- Comprehensive product portfolio.
- Strong relationships with surgeons and hospitals.
- Innovative product development.
Weaknesses
- Negative profit margin.
- High beta, indicating higher volatility.
- Reliance on a specialized market segment.
- Limited geographic diversification.
Catalysts
- New product launches in plating systems and orthobiologics are expected to drive revenue growth in the next 6-12 months.
- Expansion of the sales and distribution network into new geographic markets is expected to increase market penetration.
- Strategic acquisitions of complementary businesses and technologies can broaden the product portfolio and expand market reach.
Risks
- Competition from larger medical device companies could impact market share and pricing.
- Regulatory changes and healthcare reforms could affect product approvals and reimbursement rates.
- Product liability claims and recalls could result in financial losses and reputational damage.
- The company's negative profit margin poses a risk to its long-term financial sustainability.
Growth Opportunities
- Expanding Product Portfolio: Paragon 28 can drive growth by continually innovating and expanding its product offerings within the foot and ankle surgical market. This includes developing new plating systems, precision guides, and orthobiologics to address a wider range of conditions and surgical techniques. The market for foot and ankle devices is expected to grow, driven by technological advancements and increasing demand for minimally invasive procedures. A robust R&D pipeline and strategic acquisitions can accelerate this growth, with a potential market size expansion of 10-15% annually over the next 3-5 years.
- Geographic Expansion: Paragon 28 has the opportunity to expand its sales and distribution network into new international markets. This includes targeting regions with growing healthcare spending and an increasing prevalence of foot and ankle disorders. Entering new markets requires regulatory approvals, establishing distribution partnerships, and adapting products to local market needs. Successful geographic expansion could increase revenue by 20-25% over the next 5 years, tapping into a global market for orthopedic devices.
- Strategic Acquisitions: Paragon 28 can pursue strategic acquisitions of complementary businesses and technologies to broaden its product portfolio and expand its market reach. This includes acquiring companies with innovative products, established distribution networks, or specialized expertise in specific areas of foot and ankle surgery. Acquisitions can accelerate growth, enhance competitive positioning, and create synergies. The timeline for acquisitions depends on market opportunities and available capital, with potential for 1-2 acquisitions per year.
- Increasing Market Penetration: Paragon 28 can increase its market share by strengthening its relationships with hospitals and ambulatory surgery centers. This includes providing comprehensive training and support to surgeons, offering competitive pricing and financing options, and developing customized solutions to meet the specific needs of its customers. Increasing market penetration requires a strong sales and marketing effort, as well as a focus on customer satisfaction. A 5-10% increase in market share over the next 3 years is achievable through targeted sales initiatives.
- Focus on Minimally Invasive Procedures: With the increasing demand for minimally invasive surgical techniques, Paragon 28 can focus on developing and promoting products that enable these procedures. This includes designing smaller, more precise instruments and implants, as well as providing training and support to surgeons on how to perform minimally invasive foot and ankle surgery. The market for minimally invasive surgical devices is growing rapidly, driven by the benefits of reduced pain, faster recovery times, and improved cosmetic outcomes. A focus on minimally invasive procedures can drive revenue growth by 15-20% over the next 4 years.
Opportunities
- Expanding product portfolio through innovation and acquisitions.
- Geographic expansion into new international markets.
- Increasing market penetration through stronger customer relationships.
- Focusing on minimally invasive procedures.
Threats
- Competition from larger medical device companies.
- Pricing pressures from hospitals and healthcare providers.
- Regulatory changes and healthcare reforms.
- Product liability claims and recalls.
Competitive Advantages
- Specialized Focus: Paragon 28's exclusive focus on foot and ankle surgery allows it to develop deep expertise and tailored solutions.
- Comprehensive Product Portfolio: The company offers a wide range of products covering various foot and ankle conditions and procedures.
- Strong Relationships: Established relationships with surgeons and hospitals provide a competitive advantage.
- Innovation: Continuous innovation and development of new products drive growth and differentiation.
About FNA
Founded in 2010 and headquartered in Englewood, Colorado, Paragon 28, Inc. is dedicated to improving patient outcomes through innovative surgical solutions for the foot and ankle. The company's comprehensive product portfolio includes plating systems like the Gorilla and Silverback systems, precision guide technology for procedures such as bunion correction and ankle fusion, and a range of orthobiologics including bone grafts and synthetic materials. These products are designed to address a variety of conditions, from fractures and deformities to joint fusions and soft tissue repairs. Paragon 28 serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors, both in the United States and internationally. The company's commitment to innovation and specialized focus on the foot and ankle segment allows it to offer tailored solutions and capture a significant share of this growing market. Paragon 28's focus on innovation and customer service has allowed it to establish a strong presence in the foot and ankle surgical market.
What They Do
- Designs and develops surgical systems for foot and ankle procedures.
- Manufactures plating systems for fracture fixation and reconstruction.
- Offers precision guide technology for bunion correction and ankle fusion.
- Provides orthobiologics, including bone grafts and synthetic materials.
- Distributes products to hospitals and ambulatory surgery centers.
- Offers soft tissue fixation systems and related instruments.
- Provides total ankle replacement systems.
Business Model
- Designs, develops, and manufactures foot and ankle surgical systems.
- Sells products through a network of sales representatives and stocking distributors.
- Generates revenue from the sale of plating systems, precision guides, and orthobiologics.
- Provides training and support to surgeons on the use of its products.
Industry Context
Paragon 28, Inc. operates within the medical device industry, specifically focusing on the foot and ankle surgical market. This segment is driven by an aging population, increasing prevalence of diabetes and obesity, and advancements in surgical techniques. The market is competitive, with companies like CBIO and CSII offering similar products and solutions. Paragon 28 differentiates itself through its specialized focus on foot and ankle, a comprehensive product portfolio, and a strong network of sales representatives and stocking distributors. The global orthopedic devices market is projected to reach $60 billion by 2028, with the foot and ankle segment representing a significant portion of this market.
Key Customers
- Hospitals
- Ambulatory surgery centers
- Orthopedic surgeons specializing in foot and ankle procedures
Financials
Chart & Info
Paragon 28, Inc. (FNA) stock price: Price data unavailable
Latest News
-
Earnings Scheduled For November 12, 2024
benzinga · Nov 12, 2024
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Oct 4, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FNA.
Price Targets
Wall Street price target analysis for FNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates FNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Albert DaCosta
CEO
Albert DaCosta serves as the CEO of Paragon 28, Inc. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and business development. Prior to joining Paragon 28, he held leadership positions at various medical technology companies, where he was responsible for driving growth, innovation, and market expansion. DaCosta's expertise spans product development, sales and marketing, and operations. He is known for his ability to build high-performing teams and execute strategic initiatives.
Track Record: Under Albert DaCosta's leadership, Paragon 28 has experienced significant growth and market expansion. He has overseen the launch of several innovative products, strengthened the company's relationships with key customers, and expanded its geographic reach. DaCosta has also played a key role in driving operational efficiencies and improving the company's financial performance. His strategic vision and execution have been instrumental in positioning Paragon 28 as a leader in the foot and ankle surgical market.
Paragon 28, Inc. Healthcare Stock: Key Questions Answered
What does Paragon 28, Inc. do?
Paragon 28, Inc. specializes in the design, development, and distribution of surgical solutions for the foot and ankle market. The company offers a comprehensive portfolio of plating systems, precision guides, orthobiologics, and soft tissue fixation systems. These products are used by orthopedic surgeons to treat a wide range of foot and ankle conditions, including fractures, deformities, and joint fusions. Paragon 28 serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors, both in the United States and internationally. The company's focus on innovation and specialized expertise in the foot and ankle segment allows it to offer tailored solutions and capture a significant share of this growing market.
What do analysts say about FNA stock?
Analyst coverage of Paragon 28, Inc. (FNA) is still developing, reflecting its relatively recent entry into the public market. Current analysis focuses on the company's growth potential within the foot and ankle surgical market, driven by its specialized product portfolio and expanding sales network. Key valuation metrics include market capitalization, revenue growth, and gross margin. Analysts are closely monitoring the company's ability to achieve profitability and manage its operating expenses effectively. The consensus view is that FNA presents a compelling growth opportunity, but investors should be aware of the risks associated with its negative profit margin and high beta.
What are the main risks for FNA?
Paragon 28, Inc. faces several risks, including competition from larger medical device companies, regulatory changes and healthcare reforms, and product liability claims. The company's negative profit margin poses a risk to its long-term financial sustainability, requiring careful management of operating expenses and revenue growth. Additionally, the company's reliance on a specialized market segment makes it vulnerable to changes in demand or technological advancements in the foot and ankle surgical market. Investors should also consider the company's high beta, which indicates higher volatility compared to the market. These risks could impact FNA's financial performance and stock price.
How does Paragon 28, Inc. manage regulatory risks associated with medical devices?
Paragon 28, Inc. operates in a highly regulated industry, requiring adherence to stringent standards set by regulatory bodies like the FDA in the United States. The company manages these risks through a robust quality management system, ensuring compliance with pre-market clearance and post-market surveillance requirements. This includes rigorous testing, documentation, and reporting procedures. They also maintain close communication with regulatory agencies to stay informed about evolving guidelines and proactively address potential issues. This comprehensive approach minimizes the risk of product recalls, delays in market entry, and potential legal liabilities, safeguarding the company's reputation and market position.
What is Paragon 28, Inc.'s strategy for protecting its intellectual property?
Paragon 28, Inc. relies on a combination of patents, trademarks, and trade secrets to protect its intellectual property and maintain a competitive advantage in the foot and ankle surgical market. The company actively seeks patent protection for its innovative products and technologies, both in the United States and internationally. It also uses trademarks to protect its brand and prevent competitors from using similar names or logos. Furthermore, Paragon 28 implements strict confidentiality agreements and security measures to protect its trade secrets and proprietary information. This multi-faceted approach helps to prevent infringement, maintain market exclusivity, and preserve the value of its intellectual property assets.
What are the key factors to evaluate for FNA?
Paragon 28, Inc. (FNA) currently holds an AI score of 51/100, indicating moderate score. Key strength: Specialized focus on the foot and ankle market. Primary risk to monitor: Competition from larger medical device companies could impact market share and pricing. This is not financial advice.
How frequently does FNA data refresh on this page?
FNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FNA's recent stock price performance?
Recent price movement in Paragon 28, Inc. (FNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on the foot and ankle market. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.